Company Profile
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the manufacture and sale of pharmaceutical products in Mainland China, other Asian regions, Europe, North America, and internationally. It operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. The company provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson's disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent infection induced by chemotherapy; and Keaili for breast cancer. It also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries. In addition, the company provides Debixin for various ulcer; Qimaite for acute and chronic pains; antibiotics, vitamin C, and caffeine APIs; functional food products; and healthcare services. It has a strategic collaboration with AstraZeneca PLC to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications and multiple therapies for obesity and type 2 diabetes. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People's Republic of China.
Latest News
KPMG barred from competing for government work in Victoria – report
HKTB's Hong Kong Summer Fun Adds Ticket Spending Offers
Galaxy Digital (GLXY) Could Be 46% Undervalued Following Its Onchain Yield Push
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Website | https://www.cspc.com.hk |
| Audit Risk | 6 |
| Board Risk | 7 |
| Overall Risk | 10 |
| Market Cap | 94.67B |
| Trailing P/E | 21.28 |
| Forward P/E | 11.66 |
| Dividend Rate | 0.3 |
| Dividend Yield | 3.51% |
| Trailing Annual Div. Rate | 0.26 |
| Trailing Annual Div. Yield | 3.05% |
| Trailing EPS | 0.39 |
| Forward EPS | 0.71 |
| Book Value | 3.36 |
| Price-to-Book | 2.47 |
| Enterprise-to-Revenue | 3.5 |
| Enterprise-to-EBITDA | 19.44 |
| Ex-Dividend Date | 06/24/2026 |
| Earnings Date | 08/27/2026 |
| Earnings Call Date | |
| Revenue Average | 8.44B |
| Revenue Low | 7.99B |
| Revenue High | 8.96B |